ClinicalTrials.gg
CompletedNCT03939429Updated Oct 10, 2022

Phase 1 Study of Oral QPX2015 in Healthy Adult Subjects

A Phase 1 interventional study of QPX2015 and Placebo oral capsule in Bacterial Infections, sponsored by Qpex Biopharma, Inc.. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-10.

Sponsored by Qpex Biopharma, Inc. (part of Shionogi) · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Bacterial Infections by Shionogi — none open to participants now, none under way, none of them phase 3. Bacterial Infections · Shionogi.

Started
2019
the only one that year
Phase 1
9 of 10
none open now
Registered
2nd of 10
by date

Among the 10 studies in Bacterial Infections by Shionogi, this one is the only one that started in 2019, is one of 9 in phase 1, and was the 2nd registered.

Bacterial Infections

586 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

Browse Bacterial Infections studies →

Open to participants now

None of the 10 studies in Bacterial Infections by Shionogi is open now. The open studies under Bacterial Infections, anywhere →

Where they have run

Who these studies take

Of the 56 Bacterial Infections studies recruiting now, 38 (68%) set no upper age limit and 13 (23%) stop at 75 or younger; 18 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Bacterial Infections by Shionogi as a file.
02

Study summary

QPX2015 (beta-lactam antibiotic) is being studied at higher than approved doses to combine with a new beta-lactamase inhibitor to treat bacterial infections, including those due to multi-drug resistant bacteria.

Read the detailed description

The worldwide spread of resistance to antibiotics among gram-negative bacteria, particularly members of the ESKAPE group of pathogens, has resulted in a crisis in the treatment of both hospital acquired and community acquired infections. In particular, the increase in Enterobacteriaceae expressing extended spectrum beta-lactamases (ESBLs) and carbapenemases that are resistant to all oral beta-lactams and fluoroquinolones in the community have resulted in many patients requiring admission just for IV antibiotics to treat their infections.

Qpex Biopharma is developing a fixed combination antibiotic of QPX2015 (beta-lactam antibiotic) plus a new beta-lactamase inhibitor.

03

Conditions studied

  • Bacterial Infections

Browse trials for

Keywords

  • beta-lactam antibiotic
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult males and/or females of non-child bearing potential, 18 to 55 years of age (inclusive).
  2. (BMI) ≥ 18.5 and ≤ 29.9 (kg/m2) and weight between 55.0 and 100.0 kg (inclusive).
  3. Medically healthy with clinically insignificant screening results (e.g., laboratory profiles, medical histories, [ECGs], physical examination) as assessed by the PI.
  4. Voluntarily consent to participate in the study.
  5. If male, agree to be sexually abstinent or agree to use two approved methods of when engaging in sexual activity from study check-in through completion of the end-of-study. Subjects must agree to use two approved methods of contraception for 30 days following the last administration of the study drug, and to not donate sperm during this same period of time. In the event that the sexual partner is surgically sterile, contraception is not necessary.
  6. Females of non- with serum FSH levels ≥ 40 mIU/mL are either (defined as 12 months spontaneous amenorrhea) or have undergone sterilization procedures at least 6 months prior to dosing.

Exclusion criteria

Exclusion Criteria:

  1. History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease.
  2. Positive urine drug/alcohol testing at screening or check-in (Day -1).
  3. Positive testing for , or C
  4. History or presence of alcoholism or drug abuse within last 2 years
  5. Use of more than 5 packs/week of tobacco/nicotine-containing product within last 6 months prior dosing.
  6. Use of any prescription medication (with the exception of hormonal or hormone replacement therapy for females) within 14 days prior to dosing.
  7. Use of any over-the-counter (OTC) medication, including herbal products and vitamins, within the 7 days prior to dosing.
  8. Use of antacids, H2 receptor blockers or proton pump inhibitors 3 days prior to dosing.
  9. History of any or allergic reaction to cephalosporins, penicillins, carbapenems, or monobactams).
  10. Participation in another clinical trial within 30 days prior to Dosing or within 5 half-lives of the previous investigational drug, whichever is longer.
  11. Females who are pregnant or lactating.
  12. interval >450 msec, or history of prolonged QT syndrome at screening or check-in
  13. Calculated less than 80 mL/min (Cockcroft-Gault method) at screening or check-in.
  14. Subjects who have any abnormalities on laboratory values: White blood cell count \< 3,000/mm3, \< 11g/dL or \< 1,200/mm3 or count \< 120,000/mm3.
  15. Liver function abnormalities defined by an elevation in , or ALT 1.5 x of the normal range for subjects based on age and sex.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    QPX2015

    QPX2015, antibiotic

    Drug: QPX2015

  • Placebo comparator
    Placebo

    Matched placebo

    Drug: Placebo oral capsule

Interventions

  • DrugQPX2015

    antibiotic

    Also known as: oral dose

  • DrugPlacebo oral capsule

    Placebo comparator

    Also known as: oral dose

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment -Emergent Adverse events by subject and by cohort

    Number of patients with Treatment-Emergent AEs by treatment arm, severity and relationship to treatment

    Time frame: Study Day 1 to 13

  2. Number of patients with changes from baseline in safety parameters

    Number of patients with changes in safety parameters before and after dosing by subject and treatment arm

    Time frame: Study Day 1 to 13

  3. Peak plasma Concentration measurements by subject and by cohort (Cmax)

    Comparison will be performed between the cohorts for Cmax. Mean graphical presentation of the data will be reported. Statistical analysis of exposure parameters will be performed.

    Time frame: Study Day 1 to 13

  4. Time concentration data measurements by subject and by cohort (Tmax)

    Comparison will be performed between the cohorts for Tmax.

    Time frame: Study Day 1 to 13

  5. Area under the plasma concentration versus time curve (AUC) between cohorts

    Comparison will be performed between the cohorts for AUC. Mean graphical presentation of the data will be reported. Statistical analysis of exposure parameters will be performed.

    Time frame: Study Day 1 to 13

  6. Urine PK amount excreted by subject and by cohort

    Urine PK parameters such as amount excreted will be calculated from urinary excretion data

    Time frame: Study Day 1 to 13

  7. Urine PK % dose excreted by subject and by cohort

    Urine PK parameters such as amount of % dose excreted will be calculated from urinary excretion data

    Time frame: Study Day 1 to 13

07

Study locations

1 site
  • CMAX
    Adelaide, South Australia, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Oct 2019, 4 months.

Of 52 industry-sponsored phase 1 interventional studies under Bacterial Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 4 months is below that.

Counting every sponsor, half of 67 studies reached it within 9 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2019
First posted
May 6, 2019
StartActual
May 20, 2019
Primary completionActual
Oct 6, 2019
CompletionActual
Oct 6, 2019
Last update
Oct 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03939429
Collaborators
Biomedical Advanced Research and Development Authority
Responsible party
Sponsor
First posted
May 6, 2019
Start date
May 20, 2019
Primary completion
Oct 6, 2019
Completion
Oct 6, 2019
Last update
Oct 10, 2022

Study contacts

Jeffery S Loutit, MBChB
study director · Qpex Biopharma, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion